512529 Stock Overview Operates in the veterinary healthcare business in Europe, Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sequent Scientific Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Sequent Scientific Historical stock prices Current Share Price ₹178.50 52 Week High ₹240.90 52 Week Low ₹91.85 Beta 0.81 1 Month Change -8.53% 3 Month Change 2.97% 1 Year Change 51.08% 3 Year Change 13.62% 5 Year Change 149.83% Change since IPO 1,568.22%
Recent News & Updates
Sequent Scientific Limited Announces Executive Changes Dec 19
Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024) Nov 14
Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 07
Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director Oct 28 Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million Sep 28
Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion. Sep 27
See more updates
Sequent Scientific Limited Announces Executive Changes Dec 19
Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024) Nov 14
Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 07
Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director Oct 28 Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million Sep 28
Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion. Sep 27
Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024 Aug 27
Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API Aug 21
New major risk - Financial position Aug 16
Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024 Aug 09
New minor risk - Share price stability Jul 15
Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023) May 16
Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024 May 10
Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024 Apr 04
Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023) Feb 14
Sequent Scientific Limited Announces Executive Changes Feb 13
Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024 Feb 07
Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024 Dec 06
Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023 Oct 31
Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer Oct 17
Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023 Aug 09
Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023 Aug 05 Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra Jul 15
Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022) May 24
Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022) Feb 15
Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director Dec 08
Price target decreased to ₹149 Nov 16
High number of new and inexperienced directors Nov 16
Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022) Nov 09
Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion. Nov 08 Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022
Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022 Aug 27
First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022) Aug 10
Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022 Aug 03
Investor sentiment improved over the past week Jul 20
Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer Jul 16
Investor sentiment deteriorated over the past week Jun 20
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 27
Investor sentiment improved over the past week May 23
Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022 May 20
Price target decreased to ₹170 Apr 27
High number of new and inexperienced directors Apr 27
Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022 Apr 15 Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director
CEO, MD & Executive Director recently sold ₹73m worth of stock Apr 06
Investor sentiment improved over the past week Apr 04
CEO, MD & Executive Director recently sold ₹84m worth of stock Mar 28
CEO, MD & Executive Director recently sold ₹23m worth of stock Mar 06
Investor sentiment deteriorated over the past week Feb 24
CEO, MD & Executive Director recently sold ₹27m worth of stock Feb 23
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 13
Price target decreased to ₹197 Jan 25
Insider recently sold ₹5.7m worth of stock Jan 05
Investor sentiment deteriorated over the past week Nov 30
Insider recently bought ₹1.4m worth of stock Nov 13
Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021) Nov 04
Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021) Nov 04
Investor sentiment deteriorated over the past week Oct 22
Insider recently sold ₹17m worth of stock Sep 09
Insider recently sold ₹17m worth of stock Aug 27
Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020) Jul 03
Investor sentiment improved over the past week Jun 30
Investor sentiment improved over the past week Apr 28
Insider recently sold ₹1.3m worth of stock Feb 21
Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020) Feb 04
New 90-day high: ₹232 Feb 03
Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021 Jan 26
Investor sentiment improved over the past week Jan 19
New 90-day high: ₹214 Jan 19
New 90-day high: ₹181 Jan 04
Chief Financial Officer recently sold ₹7.7m worth of stock Dec 22
Sequent Scientific Limited Appoints Fabian Kausche as an Additional (Non-Executive Non-Independent) Director Dec 16
Insider recently sold ₹8.7m worth of stock Dec 10
New 90-day high: ₹168 Dec 07
Sequent Scientific Limited Announces Launch of Inhouse Developed Halofusol® in EU Dec 03
Insider recently sold ₹79m worth of stock Nov 25
Insider recently sold ₹3.8m worth of stock Nov 14
Second quarter 2021 earnings released: EPS ₹0.86 Nov 08
Sequent Scientific Limited Appoints Gregory John Andrews as an Additional Director with Effect from November 6, 2020 Nov 07
Sequent Scientific Limited to Report Q2, 2021 Results on Nov 06, 2020 Nov 01
Insider recently sold ₹77m worth of stock Oct 03
New 90-day high: ₹159 Sep 28
Pronomz Ventures LLP completed the acquisition of 3.7% stake in Strides Pharma Science Limited (NSEI:STAR) from Sequent Scientific Limited (BSE:512529) Sep 26 Sequent Scientific Limited Announces Receipt of WHO - Geneva Approval for API Praziquantel (Anthelmintic) Under Pre-Qualification Program
CEO, MD & Executive Director recently sold ₹4.3m worth of stock Sep 13
New 90-day high - ₹146 Sep 11
Insider recently sold ₹38.8m worth of stock Aug 27
Sequent Scientific Limited (BSE:512529) agreed to acquire an additional unknown minority stake in Provet Veteriner Urunleri San. VeTic. A.S. Aug 13
Sequent Scientific Limited to Report Q1, 2021 Results on Jul 30, 2020 Jul 31 Shareholder Returns 512529 IN Pharmaceuticals IN Market 7D -5.9% 1.8% -2.1% 1Y 51.1% 43.7% 22.5%
See full shareholder returns
Return vs Market: 512529 exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility Is 512529's price volatile compared to industry and market? 512529 volatility 512529 Average Weekly Movement 8.3% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 512529's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 512529's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products.
Show more Sequent Scientific Limited Fundamentals Summary How do Sequent Scientific's earnings and revenue compare to its market cap? 512529 fundamental statistics Market cap ₹44.51b Earnings (TTM ) ₹164.81m Revenue (TTM ) ₹14.49b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 512529 income statement (TTM ) Revenue ₹14.49b Cost of Revenue ₹8.10b Gross Profit ₹6.39b Other Expenses ₹6.23b Earnings ₹164.81m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.66 Gross Margin 44.10% Net Profit Margin 1.14% Debt/Equity Ratio 60.9%
How did 512529 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 18:33 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sequent Scientific Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Nikhil Shetty BP Wealth Management Private Limited null null IIFL Wealth Management Ltd.
Show 0 more analysts 
